PDI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Perit Dial Int 17(1): 17-21 1997
© 1997 International Society for Peritoneal Dialysis
This Article
Right arrow Full Text (PDF)
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Feriani, M
Right arrow Articles by Passlick-Deetjen, J
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Feriani, M
Right arrow Articles by Passlick-Deetjen, J
Peritoneal Dialysis International, Vol 17, Issue 1, 17-21
Copyright © 1997 by International Society for Peritoneal Dialysis

Clinical Trial

Clinical experience with a 39 mmol/L bicarbonate-buffered peritoneal dialysis solution

M Feriani, C Carobi, G La Greca, U Buoncristiani, and J Passlick-Deetjen

Department of Nephrology, St. Bortolo Hospital, Vicenza, Italy.

OBJECTIVE: To investigate the effect on the patient's acid-base status of a 39 mmol/L bicarbonate-buffered continuous ambulatory peritoneal dialysis (CAPD) solution. DESIGN: This was an open, controlled, cross-over, two-center study in 9 patients. After three months of treatment with a 34 mmol/L bicarbonate-buffered solution (t0) patients were switched to a 39 mmol/L bicarbonate-containing solution for four weeks. At the end of the study period (t4) patients were again treated with a 34 mmol/L bicarbonate-buffered CAPD solution for one month (t8). RESULTS: Mean venous plasma bicarbonate level significantly increased during the study and decreased at the baseline level during the control period (t0 = 22.94 +/- 2.54, t1 = 26.74 +/- 3.07, t2 = 28.47 +/- 2.68, t3 = 28.11 +/- 3.56, t4 = 28.71 +/- 3.27, t8 = 24.94 +/- 2.56). Arterial blood pH and plasma bicarbonate significantly increased during the study and significantly decreased at the end of the control period (pH: t0 = 7.37 +/- 0.04, t4 = 7.42 +/- 0.04, t8 = 7.37 +/- 0.06. Bicarbonate: t0 = 21.97 +/- 2.57, t4 = 25.85 +/- 2.02, t8 = 21.87 +/- 2.89). The changes in plasma bicarbonate during the study period were inversely correlated with the metabolic acid production calculated from the protein catabolic rate and with the apparent distribution space for bicarbonate (ABS) of patients. CONCLUSIONS: The 39 mmol/L bicarbonate-buffered CAPD solution improved the patient's acid-base status. Potential undesirable metabolic alkalosis could be prevented by analyzing the ABS and the metabolic acid production of patients.




This article has been cited by other articles:


Home page
 Nephrol Dial TransplantHome page
S. Ogata, T. Naito, N. Yorioka, K. Kiribayashi, M. Kuratsune, and N. Kohno
Effect of lactate and bicarbonate on human peritoneal mesothelial cells, fibroblasts and vascular endothelial cells, and the role of basic fibroblast growth factor
Nephrol. Dial. Transplant., November 1, 2004; 19(11): 2831 - 2837.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
M. Feriani, J. Passlick-Deetjen, I. Jaeckle-Meyer, and G. La Greca
Individualized bicarbonate concentrations in the peritoneal dialysis fluid to optimize acid-base status in CAPD patients
Nephrol. Dial. Transplant., January 1, 2004; 19(1): 195 - 202.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
R. Gokal
Peritoneal Dialysis in the 21st Century: An Analysis of Current Problems and Future Developments
J. Am. Soc. Nephrol., January 1, 2002; 13(90001): S104 - 115.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Multimed Inc. logo
Copyright © 1997 by Multimed Inc.